Chemed (CHE) has announced a quarterly cash dividend of $0.70 per share, a 17% increase from June’s $0.60 payout. The dividend is payable on September 3, 2026, to shareholders of record on August 17.
See our latest analysis for Chemed.
At a latest share price of US$534.88, Chemed’s 30-day share price return of 6.11% and 90-day share price return of 21.74% point to building momentum, while the 1-year total shareholder return of 18.42% reflects steady longer term gains.
If this kind of steady performance has your attention, it could be a good moment to broaden your watchlist with a fresh set of ideas using the 41 healthcare AI stocks
For Chemed, the recent share price strength and richer dividend can hint at a business that investors see as resilient, or simply show sentiment catching up after a quieter spell. How does the current valuation line up with that story?
Most Popular Narrative: 9.3% Undervalued
Chemed last closed at $534.88, while the most followed narrative places fair value at $590. This gap is built on detailed long term forecasts rather than short term price action.
VITAS is repositioning its admission mix away from an unusually high share of short-stay, hospital based patients toward a more balanced pattern that historically supports higher average daily census, which could feed through to steadier revenue growth and stronger EBITDA margins over time.
Read the complete narrative. Read the complete narrative.
Curious what kind of revenue profile and margin shift would need to sit behind that fair value for Chemed. The narrative leans on specific growth, profitability and valuation assumptions that go well beyond a simple P/E snapshot.
Result: Fair Value of $590 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Chemed’s story could change quickly if hospice admission mix shifts fail to support margins or if higher digital lead costs keep Roto Rooter profitability under pressure.
Find out about the key risks to this Chemed narrative.
Next Steps
With Chemed carrying both watchlist worthy strengths and clear risk flags, this is a good moment to look through the numbers yourself and form your own stance. To weigh those trade offs in one place, review the 2 key rewards and 1 important warning sign
Looking for more ideas beyond Chemed?
If Chemed is already on your radar, this can be a useful time to widen your opportunity set using a few focused stock screens that highlight different strengths.
- Explore potential turnaround opportunities by checking out select high conviction smaller companies through the 21 elite penny stocks with strong financials.
- Focus on quality at a measured price using the 50 high quality undervalued stocks, which filters for fundamentals and reasonable valuations.
- Prioritise resilience and balance sheet strength with the solid balance sheet and fundamentals stocks screener (50 results) so you are not missing sturdier options alongside Chemed.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com